TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC BioPharm (NASDAQ: TCBP) reported significant progress in 2024, highlighting achievements in its ACHIEVE UK trial for TCB008, where 8 patients have been dosed, including 2 completing all 4 doses. The company expanded trial sites, including Guy's and St. Thomas Hospital, with two more sites planned for Q1 2025. Key developments include signing two LOIs for acquisitions, initiating Mpox treatment research, and forming an AI partnership for donor screening. Financial highlights include a 50% reduction in Q1 cash burn and raising $8 million in Q3. Manufacturing improvements have increased treatment capacity from 52 to over 1,000 patients annually, with an 85% cost reduction per treatment.

TC BioPharm (NASDAQ: TCBP) has officially refuted false social media claims regarding its potential delisting from Nasdaq. The company, which develops allogeneic gamma-delta T cell therapies, addressed rumors from a now-deleted social media post that incorrectly stated the company had filed an 8-K Notice to delist. TC BioPharm confirmed it remains fully compliant with all Nasdaq listing requirements and will continue trading on the exchange. The company indicated it will take action to defend against such misleading claims aimed at creating negative market dynamics.

TC BioPharm (NASDAQ: TCBP) has announced a research planning collaboration with Dr. Carlos Maluquer de Motes for developing a treatment for Monkeypox. Dr. Maluquer de Motes is a Reader and Principal Investigator at the University of Surrey, with expertise in viral diseases. TC BioPharm believes their lead therapeutic TCB008 could play a important role in treating Mpox and other infectious diseases by providing a bolstered level of gamma delta t-cells to generate a more effective immune response.

The company also plans to explore TCB008's use in a prophylactic setting for infectious diseases, potentially supporting immune-compromised patients or those at high risk of infection. Mpox, an infectious viral disease affecting humans and animals, has seen over 100,000 confirmed cases and 200 deaths globally since monitoring began in 2022, according to the World Health Organization.

TC BioPharm (NASDAQ: TCBP) has announced a partnership with Carnegie Mellon University to develop an artificial intelligence solution for optimizing donor screening and matching processes in cell therapy. The company will collaborate with Dr. Wei Wu from the Ray and Stephanie Lane Computational Biology Department to leverage AI in addressing the 'big data problem' of donor variability and patient matching.

The initiative aims to enhance manufacturing yields, improve production processes, and potentially boost patient outcomes. Bryan Kobel, CEO of TC BioPharm, emphasized the significance of this partnership in advancing the cell therapy industry and addressing challenges beyond current HLA matching processes. Dr. Wu highlighted the potential of AI to transform precision medicine and personalized cell therapies.

TC BioPharm (NASDAQ: TCBP) has announced the opening of a new site for its ACHIEVE UK Trial at Guys and St. Thomas Hospital in London. This leading hospital, known for its extensive experience in cell therapy and oncology trials, will contribute to increasing enrollment velocity for the study. Dr. Hugues de Lavallade, a consultant hematologist with over 10 years of experience in myeloid disorders, will serve as the Principal Investigator.

The ACHIEVE clinical trial, which is evaluating TCB008 in patients with AML or MDS/AML, has been progressing positively since a dose increase earlier this year. The company reports strong enrollment and remains on schedule for data release in the first half of 2025. TC BioPharm's Executive VP of Clinical, Alison Bracchi, expressed enthusiasm about the positive feedback from clinicians and the AML community as they continue to activate new sites for this phase II, open-label study.

TC BioPharm, a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced its participation in the 2024 ThinkEquity Conference in New York City. CEO Bryan Kobel will present on October 30, 2024, at the Mandarin Oriental Hotel.

Kobel plans to discuss TC BioPharm's clinical trials and recent balance sheet improvements. The ThinkEquity Conference is a prominent event showcasing emerging growth companies from various sectors worldwide.

Interested parties can contact IR@tcbiopharm.com for more information or to schedule meetings with management. TC BioPharm trades on NASDAQ under the ticker TCBP.

TC BioPharm (NASDAQ: TCBP) has announced significant progress in its ACHIEVE Phase 2b clinical trial for TCB008, an allogeneic gamma-delta T cell therapy for cancer. The trial, focusing on patients with AML or MDS/AML, has reached a important milestone with the first patient completing the full dose regimen of approximately one billion cells. Importantly, no TCB008-related adverse events have been observed in any of the restart patients.

Key highlights include:

• 6 patients received a second dose
• 3 patients received a third dose
• 1 patient received a fourth dose
• 3 more patients expected to complete the full regimen by September's end

The company anticipates enrolling 24 patients in Cohort A and expects to announce a full data set, including primary and secondary endpoints, in the first half of 2025.

TC BioPharm (NASDAQ: TCBP) announces significant progress in its ACHIEVE Phase 2b clinical trial for TCB008, an allogeneic gamma-delta T cell therapy for cancer. The first patient has completed the full dose regimen, receiving approximately one billion cells across four doses, with no drug-related adverse events observed. This milestone supports the safety profile of TCB008 and the study's safety objectives.

Key updates include:

• 6 patients received a second dose
• 3 patients received a third dose
• 1 patient received all four doses
• 3 more patients expected to complete the full regimen by September's end

The ACHIEVE trial aims to enroll 24 patients in Cohort A, with 14 initially receiving TCB008. Bryan Kobel, CEO of TC BioPharm, expressed satisfaction with the progress and safety profile. The company anticipates releasing a full data set, including primary and secondary endpoints, in the first half of 2025.

TC BioPharm (NASDAQ: TCBP) has announced plans to initiate Proof of Concept preclinical studies for its lead therapeutic TCB 008 in the treatment of monkeypox. TCB008 is an allogeneic unmodified cell therapy composed of activated and expanded gamma delta T (GDT) cells. The company aims to partner with a leading Infectious Disease Center or University to rapidly advance these studies.

CEO Bryan Kobel highlighted the potential of gamma delta t-cells in mounting a successful immune response against viral infections. TCBP sees this as an opportunity to expand the therapeutic applications of TCB008, particularly in rapid response to aggressive viral infections. The company believes its frozen/thawed product could potentially prevent death, reduce extended viral infection, and help contain the spread of infectious diseases like monkeypox.